Selexys' sickle cell disease drug is entering Phase II trial

08/20/2013 | Oklahoman (Oklahoma City), The

Selexys Pharmaceuticals has started patient enrollment for a midstage study of the experimental sickle cell disease drug SelG1. The trial, which will involve about 175 patients, will evaluate the drug's safety and efficacy with the goal of decreasing the frequency of sickle cell-related pain crises.

View Full Article in:

Oklahoman (Oklahoma City), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA